CN101568343A - 用于治疗癌症的方法 - Google Patents

用于治疗癌症的方法 Download PDF

Info

Publication number
CN101568343A
CN101568343A CNA200780027591XA CN200780027591A CN101568343A CN 101568343 A CN101568343 A CN 101568343A CN A200780027591X A CNA200780027591X A CN A200780027591XA CN 200780027591 A CN200780027591 A CN 200780027591A CN 101568343 A CN101568343 A CN 101568343A
Authority
CN
China
Prior art keywords
derivatives
pharmaceutically acceptable
cancer
acceptable salt
tylosin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200780027591XA
Other languages
English (en)
Chinese (zh)
Inventor
莉娜·罗西娜巴斯菲尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd filed Critical Ramot at Tel Aviv University Ltd
Publication of CN101568343A publication Critical patent/CN101568343A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CNA200780027591XA 2006-06-12 2007-06-12 用于治疗癌症的方法 Pending CN101568343A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81260506P 2006-06-12 2006-06-12
US60/812,605 2006-06-12

Publications (1)

Publication Number Publication Date
CN101568343A true CN101568343A (zh) 2009-10-28

Family

ID=38541966

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200780027591XA Pending CN101568343A (zh) 2006-06-12 2007-06-12 用于治疗癌症的方法

Country Status (7)

Country Link
US (1) US9486467B2 (https=)
EP (1) EP2029147B1 (https=)
JP (1) JP2009539970A (https=)
CN (1) CN101568343A (https=)
AT (1) ATE468119T1 (https=)
DE (1) DE602007006663D1 (https=)
WO (1) WO2007144876A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019007368A1 (zh) * 2017-07-04 2019-01-10 沈阳福洋医药科技有限公司 异戊酰螺旋霉素i、ii和/或iii在制备治疗和/或预防肿瘤药物方面的应用和药物
WO2019141254A1 (zh) * 2018-01-19 2019-07-25 沈阳福洋医药科技有限公司 一种mTOR抑制剂、药物组合物及其应用
CN110545820A (zh) * 2017-04-06 2019-12-06 沈阳福洋医药科技有限公司 可利霉素及其药学上可接受的盐在制备治疗和/或预防肿瘤药物方面的应用
CN110709408A (zh) * 2017-02-22 2020-01-17 免疫系统调节控股有限公司 新型免疫刺激大环内酯
US11413302B2 (en) 2018-01-19 2022-08-16 Shenyang Fuyang Pharmaceutical Technology Co., Ltd. Use of carrimycin or active ingredients thereof and use thereof

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2894992A1 (en) 2012-12-24 2014-07-03 Ramot At Tel-Aviv University Ltd. Agents for treating genetic diseases resulting from nonsense mutations, and methods for identifying the same
WO2015198329A1 (en) 2014-06-25 2015-12-30 Bio Blast Pharma Ltd. Injectable formulations for intrathecal administration of antibiotic agents
US11351185B2 (en) 2020-03-11 2022-06-07 Asclea Corporation Use of isovalerylspiramycins as anti-cancer agents to inhibit metastasis
WO2023283427A2 (en) * 2021-07-09 2023-01-12 Verdure Biotech, Inc. Enteric and delayed release formulations of locally bioavailable drugs (lbd) targeting the colon
WO2023114231A1 (en) * 2021-12-14 2023-06-22 The Regents Of The University Of California Clustered mutations for the treatment of cancer

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4092473A (en) 1975-08-01 1978-05-30 Sanraku Ocean Co., Ltd. Tylosin derivatives and their manufacturing process
GB1540397A (en) 1976-12-08 1979-02-14 May & Baker Ltd Spiramycin esters
US4064143A (en) 1976-12-10 1977-12-20 Pfizer Inc. Oleandomycin derivatives
US4205163A (en) 1977-11-08 1980-05-27 Sanraku-Ocean Co., Ltd. Tylosin derivatives
US4124755A (en) 1978-01-03 1978-11-07 Pfizer Inc. 11-Alkanoyl-4"-deoxy-4"-isonitrilo-oleandomycin derivatives
SE445739B (sv) 1978-09-14 1986-07-14 Toyo Jozo Kk 3", 4"-diacyltylosinderivat
US4429116A (en) 1982-12-27 1984-01-31 Pfizer Inc. Alkylated oleandomycin containing compounds
US5872103A (en) * 1986-11-26 1999-02-16 Belletti; Dino A. Prevention of mammary tumors by treatment with cardiac glycosides
US5324720A (en) 1992-03-20 1994-06-28 Merck & Co., Inc. Methods of achieving antitumor activity using 16-membered-macrolide-type compounds
CA2127578A1 (en) 1993-07-08 1995-01-09 Keiichi Ajito 16-membered macrolide derivatives and process for producing the same
IL127946A0 (en) * 1996-07-08 2000-02-17 Cird Galderma Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents
AP1060A (en) 1998-01-02 2002-04-23 Pfizer Prod Inc Novel erythromycin derivatives.
HRP980646B1 (en) 1998-12-30 2008-02-29 GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. Novel oleandomycin derivatives
IL133077A0 (en) * 1999-01-29 2001-03-19 Pfizer Prod Inc Azithromycin combination for emesis control in dogs
EA200100983A1 (ru) 1999-05-24 2002-10-31 Пфайзер Продактс Инк. Производные 13-метилэритромицина
US6455680B1 (en) 2000-12-21 2002-09-24 Abbott Laboratories Methods utilizing aryl thioimines in synthesis of erythromycin derivatives
US20050171032A1 (en) 2002-04-11 2005-08-04 Children's Medical Center Corporation Methods for the treatment of cancer
CN1562066A (zh) 2004-04-14 2005-01-12 山东鲁抗舍里乐药业有限公司 酒石酸泰乐菌素颗粒剂及其制备方法
GB0417852D0 (en) * 2004-08-11 2004-09-15 Biotica Tech Ltd Production of polyketides and other natural products

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110709408A (zh) * 2017-02-22 2020-01-17 免疫系统调节控股有限公司 新型免疫刺激大环内酯
CN110709408B (zh) * 2017-02-22 2022-10-25 Isr免疫系统调节控股公共有限公司 新型免疫刺激大环内酯
CN110545820A (zh) * 2017-04-06 2019-12-06 沈阳福洋医药科技有限公司 可利霉素及其药学上可接受的盐在制备治疗和/或预防肿瘤药物方面的应用
CN110545820B (zh) * 2017-04-06 2023-01-10 沈阳福洋医药科技有限公司 可利霉素及其药学上可接受的盐在制备治疗和/或预防肿瘤药物方面的应用
WO2019007368A1 (zh) * 2017-07-04 2019-01-10 沈阳福洋医药科技有限公司 异戊酰螺旋霉素i、ii和/或iii在制备治疗和/或预防肿瘤药物方面的应用和药物
CN110869027A (zh) * 2017-07-04 2020-03-06 沈阳福洋医药科技有限公司 异戊酰螺旋霉素i、ii和/或iii在制备治疗和/或预防肿瘤药物方面的应用和药物
RU2766176C2 (ru) * 2017-07-04 2022-02-08 Шенянг Фуянг Фармасьютекал Технолоджи Ко., Лтд. Применение изовалерил-спирамицина i, ii и/или iii при изготовлении препарата для лечения и/или профилактики опухоли и получения лекарственного препарата
CN110869027B (zh) * 2017-07-04 2023-09-08 沈阳福洋医药科技有限公司 异戊酰螺旋霉素i、ii和/或iii在制备治疗和/或预防肿瘤药物方面的应用和药物
WO2019141254A1 (zh) * 2018-01-19 2019-07-25 沈阳福洋医药科技有限公司 一种mTOR抑制剂、药物组合物及其应用
CN110051845A (zh) * 2018-01-19 2019-07-26 沈阳福洋医药科技有限公司 一种mTOR抑制剂、药物组合物及其应用
US11413302B2 (en) 2018-01-19 2022-08-16 Shenyang Fuyang Pharmaceutical Technology Co., Ltd. Use of carrimycin or active ingredients thereof and use thereof

Also Published As

Publication number Publication date
WO2007144876A1 (en) 2007-12-21
ATE468119T1 (de) 2010-06-15
EP2029147A1 (en) 2009-03-04
JP2009539970A (ja) 2009-11-19
US20110306571A1 (en) 2011-12-15
EP2029147B1 (en) 2010-05-19
US9486467B2 (en) 2016-11-08
DE602007006663D1 (de) 2010-07-01

Similar Documents

Publication Publication Date Title
CN101568343A (zh) 用于治疗癌症的方法
CN107108686B (zh) 用于恶性肿瘤的rna干扰组合物和方法
EP3985118A1 (en) C/ebp alpha short activating rna compositions and methods of use
WO2019036430A1 (en) METHODS OF TREATING HEPATIC DISEASES
Wu et al. Gelatinases-stimuli nanoparticles encapsulating 5-fluorouridine and 5-aza-2′-deoxycytidine enhance the sensitivity of gastric cancer cells to chemical therapeutics
KR20090130010A (ko) 암세포 또는 암 관련 섬유아세포용 표적화제
US10548842B2 (en) Nanoliposomal c-MYC-siRNA inhibits in vivo tumor growth of cisplatin-resistant ovarian cancer
WO2019099353A9 (en) Compositions and methods for the treatment and prevention of cancer
JP6262707B2 (ja) がん幹細胞を含むまたはそれに由来するがんの治療、予防および診断のための方法および組成物
EP2886122B1 (en) Agent for treating cancer
US12480127B2 (en) siRNA, medical compositions, and methods for treating diabetes using the same
AU2012316266B2 (en) Combination therapy for chemoresistant cancers
CN116615228A (zh) 用于治疗肝脏病症的抑制剂
EP4034097A2 (en) Treatment of genetic diseases characterized by unstable mrnas
EP3999178A1 (en) Medical uses, methods and uses
JP2022521502A (ja) 脆弱ｘ精神遅滞タンパク質干渉オリゴヌクレオチドおよびその使用方法
CN108403711B (zh) 一种用于检测和治疗炎性肠病的microRNA
US20180235936A1 (en) Cancer treatment methods
CN114306280A (zh) 一种雷公藤红素纳米药物及irf1/gstm3轴在制备银屑病药物中的应用
JP2022180668A (ja) 腎機能障害の治療剤
Wang Inhibition of pancreatic cancer progression through EMT inhibition and induction of ER stress
JP2025526511A (ja) Ｆｏｘｍ１阻害剤および免疫チェックポイント阻害剤を含む癌の予防又は治療用薬学的組成物
HK40070347A (en) C/ebp alpha short activating rna compositions and methods of use
WO2022015986A1 (en) Methods for treating metastatic cancer using low dose carbon monoxide
JP2020132626A (ja) サフラナール製剤によるｃｄｃ２５ｂの抑制および阻害

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20091028